[Strategies and Barriers to the Implementation of Continuing Education in Sentinel Hospitals for the Surveillance of COVID-19 Vaccine Safety in Honduras, 2022-2023Formação continuada: estratégias e barreiras de implementação em hospitais sentinela para a vigilância da segurança das vacinas contra a COVID-19 em Honduras, 2022-2023].

Objective: To describe the continuing education strategies implemented as part of the academic training of health workers; related barriers and facilitators; and the perceptions of health workers in sentinel hospitals in Honduras regarding changes in their knowledge.

Methods: The implemented continuing education strategies are described, as are the findings of a questionnaire given to assess health workers' perceptions of the effectiveness of these strategies in the acquisition of knowledge, skills, and competencies related to the surveillance of events supposedly attributable to vaccination, immunization, or adverse events of special interest. Barriers to participation in these strategies is also described.

Catalyzing Change: Assessing Inner Setting Context of Cervical Cancer Prevention Efforts in Loreto, Peru, Prior to Transition from VIA to HPV Screen-and-Treat.

Background: The objective of this study was to understand health care providers' perspectives regarding the facilitators of and barriers to the success of the former Pap and VIA-based cervical cancer program in Iquitos, Peru, using the Consolidated Framework for Implementation Research (CFIR) to inform the transition to the HPV screen-and-treat intervention. By exploring the pre-implementation organizational context, or inner setting, through the opinions of those who would implement the HPV-based intervention at the patient care level, this research lays the foundation to assess readiness before implementation and understand what's necessary to design contextually appropriate and sustainable interventions in LMIC settings.

Methods: We conducted 19 semi-structured interviews with health professionals (12 nurse-midwives, 4 doctors, and 3 laboratory technicians) who administered the former Pap- and VIA-based cervical cancer EDT program.

In the search for new gold metalloantibiotics: In vitro evaluation of Au(III) (C^S)-cyclometallated complexes.

A series of (C^S)-cyclometallated Au(III) cationic complexes of general formula [Au(dppta)(dtc)], [Au(dppta)(azmtd)] and [Au(dppta)(azc)Cl] (dppta = N,N-diisopropyl-P,P-diphenylphosphinothioic amide-κC,S; dtc = dithiocarbamate-κS,S'; azc = azolium-2-dithiocarboxylate-κS; azmdt = azol(in)ium-2-(methoxy)methanedithiol-κS,S') were synthetized and tested against a panel of bacterial strains belonging to different Gram-positive and Gram-negative species of the ESKAPE group of pathogens. Among the tested compounds, complex 4c had the higher Therapeutic Index (TI) against multidrug resistant strains of S. aureus, S.

The iPeer2Peer mentorship program for adolescent thoracic transplant recipients: An implementation-effectiveness evaluation.

Background: An increase in self-management skills for adolescent thoracic transplant recipients may improve health outcomes and facilitate a successful transition to adulthood. The iPeer2Peer program is an online peer mentorship program that has been successfully implemented as a self-management intervention in multiple chronic disease populations. This study aimed to determine the implementation and effectiveness outcomes of the iPeer2Peer program for adolescent thoracic transplant recipients.

Liposomal formulation of a gold(III) metalloantibiotic: a promising strategy against antimicrobial resistance.

A novel lipoformulation was developed by encapsulating cationic (S^C)-cyclometallated gold(III) complex [Au(dppta)(NPy-PZ-dtc)] (AuPyPZ) in liposomes. The liposomal form of compound AuPyPZ has a bactericidal action similar to that of the free drug without any appreciable effect on the viability of mammalian cells. Furthermore, the nanoformulation reduces metalloantibiotic-induced inhibition of hERG and the inhibition of cytochromes, significantly decreasing the potential liabilities of the metallodrug.